Endo International PLC

Endo International — Investor Presentation (August 2022)

72 slides from Endo International's investor presentation, Aug 17, 2022

  1. Slide 1: Management Presentation June 2022

    Management Presentation June 2022 Confidential Subject to Confidentiality Agreement Cleansing Material Subject to FRE 408 & State Law Equivalents Preliminary and Subject to Material Change endo.com

  2. Slide 2: Disclaimer

    Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you have executed with the Company. All communications or

  3. Slide 3: Table of Contents

    Table of Contents â–º Strategy and Priorities â–º Business Segment Overview â–º Reinvent How We Work â–º Financial Projections

  4. Slide 4: Strategy and Priorities

    Strategy and Priorities

  5. Slide 5: Vision, Mission and Strategic Priorities

    Vision, Mission and Strategic Priorities Our Vision Helping everyone we serve live their best life. Our Mission We develop and deliver life-enhancing products through focused execution. Expand & Enhance Our Portfolio We are investing to build a more differentiated and durable portfolio that benefits

  6. Slide 6: Investing to Expand & Enhance Our Portfolio in core areas of growth

    We are investing to Expand & Enhance Our Portfolio by focusing our capital deployment to our core areas of growth Characteristic Medical Therapeutics Sterile Injectables Medical Aesthetics â–ªï€ Large markets in focus ($6B-$9B) â–ªï€ Large injectables market (~$12B) â–ªï€ Market size (~$2B-$3B) â–ªï

  7. Slide 7: Investments in core growth areas expected to drive revenue growth and margin expansion

    Investments in our core areas of growth are expected to drive revenue growth and margin expansion resulting in solid EBITDA growth post 2023 2023-26 revenue growth is expected to be driven by investments in our core areas of growth… …while we continue to take actions to deliver efficiencies while re

  8. Slide 8: Business Segments Overview

    Business Segments Overview

  9. Slide 9: Diversified product portfolio driven by Branded and Sterile Injectables

    We have a diversified product portfolio that will be driven by growth in Branded and Sterile Injectables Branded â–º Operates through three business units: Medical Therapeutics(1), Medical Aesthetics and Established Brands. â–º Medical Therapeutics anchored by Xiaflex®, a long-dated biologic with ac

  10. Slide 10: Branded

    Branded

  11. Slide 11: The Branded segment consists of three distinct portfolios

    The Branded segment consists of three distinct portfolios Medical Therapeutics â–º Differentiated and durable portfolio led by Xiaflex®, first and only FDA-approved non-surgical treatment for Dupuytren’s Contracture and Peyronie’s Disease â–º Ongoing commercial and R&D investment expected to drive f

  12. Slide 12: Medical Therapeutics represents a very attractive growth area

    Medical Therapeutics represents a very attractive growth area The Medical Therapeutics (MT) portfolio, which consists of Xiaflex (XPD and XDC), Supprelin LA, TLC599 and other smaller brands is expected to achieve nearly $1.0B of revenue in 2026. Ongoing commercial and R&D investments are expected to

  13. Slide 13: Integrated strategy for the Medical Therapeutics portfolio

    We have an integrated strategy to position the Medical Therapeutics portfolio for sustained future growth LEVERAGE XIAFLEX®/CCH PLATFORM • New Indications – Collagen-Based Diseases – Prioritize & Sequence New Indications Evaluation Prioritized Marketed De-Prioritized DEVELOP ENABLING TECHNOLOGIES Ne

  14. Slide 14: Continued investment in XIAFLEX R&D for new indications

    Continued investment in XIAFLEX® R&D will provide an opportunity to potentially address new indications Concept Tendon / Human Muscle Lipoma Contractures Herniated Dupuytren’s Disc Nodules Cyclops Syndrome Elbow / Hip / Spine Arthrofibrosis Collagen-Based Diseases Preclinical Clinical Marketed Post-

  15. Slide 15: Expanding the orthopedics footprint with new indications

    The orthopedics footprint can be leveraged and expanded with the launch of new XIAFLEX®, CCH XTEND and TLC-599 indications Desired Future State Approval TBD Approval 2027 Approval 2026 Hand & upper extremity orthopedics Approval 2026 Shoulder orthopedics Hip & knee orthopedics Approval 2024-25 Arthr

  16. Slide 16: TLC599 provides a 'pipeline in a product'

    Beyond catalyzing expansion to the desired future orthopedic footprint, TLC599 provides a ‘pipeline in a product’ itself Knee OA is the catalyst to capitalize on a “pipeline in a product’ asset that is highly complimentary with current Endo capabilities (i.e. Xiaflex DC) Indication Expansion Initial

  17. Slide 17: The current Medical Therapeutics pipeline is robust

    The current Medical Therapeutics pipeline is robust Phase Pipeline / Expansion Indications Asset Disease Description & MOA Hypothesis Preclinical Ph 1 Ph 2 Ph 3 • Inflammation, pain and stiffness in knee joint Osteoarthritis of the Knee TLC599 caused by erosion of articular cartilage • Long-acting s

  18. Slide 18: Medical Therapeutics growth driven by Xiaflex and new launches

    Medical Therapeutics portfolio growth is expected to be driven by Xiaflex on-market indications and new product launches Medical Therapeutics Revenue by Key Product $ million. 2023-26 CAGR 11% 2% NM NM 5% 10% [a] 17 [a] Includes Supprelin, Nascobal and Aveed Highlights/Commentary â–ªï€ Strong XPD an

  19. Slide 19: Medical Aesthetics vision

    The Medical Aesthetics vision is to build a unique portfolio through opportunistic investment in differentiated and disruptive innovations Establish Qwo® as the cornerstone cellulite treatment First and only FDA-approved injectable for treating moderate-to-severe cellulite in women Build and leverag

  20. Slide 20: Qwo has a large addressable market opportunity

    Qwo® has a large addressable market opportunity ~8.5 million U.S women are potential candidates U.S. Women Aged 25-54(1) 65 million Target BMI 18.5-29.9(2) 41 million Have some discretionary income (overall)(2)(3) 28 million Self-identify as having cellulite(2) (anywhere on the body) 12 million Self

  21. Slide 21: Qwo facing barrier to adoption; comprehensive plan

    Qwo® is facing an unexpected barrier to adoption; executing a comprehensive plan to re-establish a foundation for future success Situation Analysis • Market perceptions of the unpredictable occurrence of skin discoloration occasionally experienced with the use of QWO are deeply entrenched presenting

  22. Slide 22: The Aphrodite-1 study

    The Aphrodite-1 study will help to identify a potential solution â–ªï€ A Phase 2 study of different interventions to reduce bruising following Qwo® treatment for cellulite What of the buttocks in women â–ªï€ Multi-cohort study will test different interventions to assess their potential impact on red

  23. Slide 23: Qwo potential for long-term growth

    Qwo has the potential to provide meaningful long-term growth Medical Aesthetics Revenue $ million. 2023-26 CAGR = 107% Highlights/Commentary â–ªï€ Near-term revenue is expected to be limited as a large % of the customer base is not expected to broadly utilize Qwo until they perceived adverse event p

  24. Slide 24: Branded portfolio expected to deliver revenue and EBITDA growth

    The Branded portfolio is expected to deliver solid and sustainable revenue and EBITDA growth 2023-26 $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Medical Therapeutics $ 497 $ 629 $ 675 $ 715 $ 768 $ 842 $ 967 11% Medical Aesthestics—4 4 15 49 94 137 107% Established Brands 285 260 224 20

  25. Slide 25: Sterile Injectables

    Sterile Injectables

  26. Slide 26: Investing in differentiated products in Sterile Injectables

    We are investing in differentiated products that build on existing capabilities to increase the value of the Sterile Injectables segment Current pipeline • Develop and successfully launch products in the current pipeline New opportunities • Identify and evaluate new project opportunities that can pr

  27. Slide 27: Expanding into durable and differentiated products

    Expanding into more durable and differentiated products, while leveraging existing commercial capabilities is expected to lead to sustainable growth Developing R&D and mfg. capabilities for RTUs and other differentiated products… Drug / RTUs(1) LAIs(2) Device Differentiation …while leveraging our ho

  28. Slide 28: >35 new Sterile product candidates in development

    >35 new Sterile product candidates, of which > 50% are RTU products, are in development and expected to launch over the next 5 years Est. Number of SI Pipeline Candidates by Expected year of Launch Highlights/Commentary â–ªï€ Projects typically require 3-5 years from initiation to launch. â–ªï€ A ro

  29. Slide 29: Sterile Injectables potential growth post Vasostrict LOE

    The Sterile Injectables portfolio has the potential to deliver solid growth post the Vasostrict LOE $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Vasostrict $ 786 $ 902 $ 230 $ 52 $ 21 $ 14 $ 10 -42% Adrenalin 152 125 112 82 80 77 74 -3% Other On-Market 301 239 227 207 188 183 177 -5% Pip

  30. Slide 30: Generics and International

    Generics and International

  31. Slide 31: The Generics and International business

    The Generics and International business Generics Generics segment consists of ~150 product families, across various therapeutic areas, with demonstrated expertise in controlled release formulations. Limited reinvestment based on enterprise capital allocation priorities leads to a declining long-term

  32. Slide 32: Varenicline has potential for upside

    Varenicline has the potential for upside assuming no competition Product Overview â–ªï€ $1B US Chantix Brand Market â–ªï€ Endo is the only FDA approved Gx product Market (launched in Sept 2021) Overview â–ªï€ Nearly 50% of US market demand currently being supplied â–ªï€ Endo has ~87% of the total ma

  33. Slide 33: Generics revenue and EBITDA expected to decline

    Generics revenue and EBITDA is expected to decline as a result of limited growth investment in the portfolio $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Varenacline $—$ 60 $ 197 $ 62 $ 41 $ 31 $ 23 -42% Lubiprostone—108 103 17 16 14 13 -3% All Others 783 573 365 448 404 365 315 -5% Reve

  34. Slide 34: International portfolio not a meaningful contributor

    The International portfolio is not expected to be a meaningful contributor to revenue or EBITDA 2023-26 $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Revenue $ 99 $ 93 $ 81 $ 72 $ 68 $ 67 $ 71 -1% YoY % Δ -14% -6% -13% -11% -5% -2% 6% Gross Profit $ 63 $ 56 $ 42 $ 39 $ 37 $ 33 $ 35 -4% G

  35. Slide 35: Reinvent How We Work

    Reinvent How We Work

  36. Slide 36: Simplifying ways of working and driving efficiencies

    Simplifying our ways of working and driving efficiencies to invest back into the business has been a strategic priority over the past few years 2020 Program ~$90M of annual run-rate savings; ~500 positions eliminated â–ªï€ Transformed Gx manufacturing cost basis by shifting production to India resul

  37. Slide 37: Simplified integrated global manufacturing footprint

    We have simplified our integrated global manufacturing footprint All internally produced Generic Segment products are produced in India Rye, NY ~10 EEs; Bx Rochester, MI ~420 EEs; SI, Bx Horsham, PA ~110 EEs: Bx Cranbury, NJ ~30 EEs; Bx Indore, India (2022) ~300 EEs; SI, Gx, Mumbai, India ~70 EEs; B

  38. Slide 38: Global team size and composition has evolved

    The size and composition of the global team has evolved as a result of our transformation initiatives Number of Filled Positions 4Q20A—1Q22PF 4Q20A 4Q21A 1Q22A 1Q22PF [a] Diff % Δ USA 1,901 1,607 1,445 1,332 (569) -30% % Total 57% 50% 47% 46% India 1,263 1,457 1,462 1,387 124 10% % Total 38% 45% 47

  39. Slide 39: Financial Projections

    Financial Projections

  40. Slide 40: Key assumptions underpinning the Long-Term Plan

    There are several key assumptions underpinning our Long-Term Plan â–ªï€ Xiaflex revenue will continue to grow driven by an expected recovery in office-based procedures beginning in 2H22 coupled with a strong response to planned advertising and promotion investment in on-market indications and the la

  41. Slide 41: Revenue growth driven by Xiaflex, Qwo and Sterile launches

    Revenue growth is expected to be driven by Xiaflex, Qwo and expected new Sterile Injectable product launches 2023-26 $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Xiaflex $ 316 $ 432 $ 486 $ 530 $ 579 $ 627 $ 701 10% All Others 181 196 188 185 189 216 266 13% Medical Therapeutics $ 497 $

  42. Slide 42: Gross margin expansion beginning in 2024

    Gross margin expansion beginning in 2024 is expected to be due to product mix and cost savings initiatives 2023-26 $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Branded $ 660 $ 775 $ 786 $ 833 $ 883 $ 971 $ 1,106 10% GM% 84% 87% 87% 89% 87% 86% 86% Sterile $ 1,022 $ 1,068 $ 404 $ 233 $ 23

  43. Slide 43: EBITDA and unlevered FCF expected to grow faster than revenue

    EBITDA and unlevered FCF are expected to grow faster than revenue over the next 5 years 2023-26 $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Revenue $ 2,903 $ 2,993 $ 2,230 $ 1,937 $ 1,941 $ 2,131 $ 2,264 5% YoY % Δ 0% 3% -26% -13% 0% 10% 6% Gross Profit $ 1,945 $ 2,155 $ 1,529 $ 1,306

  44. Slide 44: Revenue and EBITDA growth driven by Branded and Sterile

    Revenue and EBITDA growth is expected to be driven by the Branded and Sterile segments 2023-26 $ million 2020A 2021A 2022E 2023E 2024E 2025E 2026E CAGR Branded $ 782 $ 894 $ 903 $ 939 $ 1,012 $ 1,127 $ 1,291 11% Sterile 1,239 1,266 581 399 400 528 551 11% Generic 783 741 665 527 461 411 352 -13% Int

  45. Slide 45: LTP opportunities and risks

    The LTP reflects uncertainties related to several opportunities and risks Area Key Opportunity Key Risk Qwo â–ªï€ Faster adoption and uptake â–ªï€ No commercially viable solution for bruising/discoloration â–ªï€ Delayed competition 6 to 24 months â–ªï€ Accelerated competition (i.e.,. number and timi

  46. Slide 46: Appendix

    Appendix

  47. Slide 47: Historical and Projected XPD+XDC Revenue

    Historical and Projected XPD+XDC Revenue CAGR Indication 2016A 2017A 2018A 2019A 2020A 2021A 2022E 2023E 2024E 2025E 2026E 2016-21 2021-26 2023-26 XPD $ 104 $ 121 $ 161 $ 207 $ 210 $ 290 $ 334 $ 374 $ 414 $ 454 $ 492 23% 11% 10% YoY % Δ 16% 33% 29% 1% 38% 15% 12% 11% 10% 8% XDC $ 86 $ 93 $ 104 $ 12

  48. Slide 48: Annex – Tax Disclosure

    Annex 1 – Tax Disclosure

  49. Slide 49: Tax Disclosure

    Tax Disclosure In connection with undertaking a preliminary analysis related to the tax consequences of a sale of its assets, the Company has identified (i) its preliminary view as to the allocation of aggregate consideration across certain material jurisdictions assuming a credit bid of all of the

  50. Slide 50: Annex – Organizational Chart

    Annex 2 – Organizational Chart

  51. Slide 51: Endo International plc organizational chart

    Confidential Subject to Confidentiality Agreement Cleansing Material ENDO INTERNATIONAL PLC Subject to FRE 408 and State Law Equivalents Preliminary and Subject to Material Change (NASDAQ: ENDP) Domicile: Ireland EFFECTIVE 4-5-22 All subsidiary companies 100% owned Endo DAC unless otherwise indicate

  52. Slide 52: Endo U.S. Inc. organizational chart

    Confidential Subject to Confidentiality Agreement Cleansing Material Endo U.S. Inc. Subject to FRE 408 and State Law Equivalents (DE) Preliminary and Subject to Material Change Endo US Holdings Endo Health Luxembourg Solutions Inc. I S.a r.l. (DE) Endo Aesthetics Hawk Acquisition Endo Luxembourg Ber

  53. Slide 53: Par Pharmaceutical Companies organizational chart

    Confidential Subject to Confidentiality Agreement Par Pharmaceutical Cleansing Material Companies, Inc. Subject to FRE 408 and State Law Equivalents Preliminary and Subject to Material Change (DE) Par Pharmaceutical, Inc. (NY) Par Laboratories Generics Kali Endo Par BioSpecifics Par Formulations Anc

  54. Slide 54: Auxilium Pharmaceuticals organizational chart

    Confidential Subject to Confidentiality Agreement Cleansing Material Subject to FRE 408 and State Law Equivalents Preliminary and Subject to Material Change Auxilium Pharmaceuticals, LLC (DE) Auxilium Auxilium International Actient US Holdings, LLC Holdings, LLC Pharmaceuticals LLC (DE) (DE) (DE) Sl

  55. Slide 55: Annex – Wind-Down Budget

    Annex 3 – Wind-Down Budget

  56. Slide 56: Project Zed Wind-Down Budget

    Project Zed Wind-Down Budget (USD in $000s, unless otherwise indicated) Preliminary Wind-Down Budget [1] Monthly Total Run Rate Costs PRE-EMERGENCE WIND-DOWN PERIOD (6 MONTHS) Wind-Down Costs 2 [2] Personnel Costs (via TSA) 3 [3] Information Technology Costs $100 $600 4 [4] TSA Costs 5 [5] Governanc

  57. Slide 57: Project Zed Footnotes

    Project Zed FOOTNOTES General: 1. The key assumptions underlying the wind-down budget include: a. Sale: All debtor assets are sold and equity of non-debtor entities are sold to a purchaser (“Purchaser”). All (x) administrative claims arising prior to the sale closing, (y) litigation claims reserves

  58. Slide 58: Wind-Down Costs footnotes

    Wind-Down Costs: 2. Personnel Costs (via TSA): Reflects finance, IT and legal personnel who are providing services via the Transition Services Agreement (“TSA”) to assist with wind-down workstreams. Wind-down budget assumes these to be provided by the Purchaser at no cost. 3. Information Technology

  59. Slide 59: Wind-down footnotes: Financial Advisor — Tax and other

    13. Financial Advisor — Tax: Reflects all-in global tax advisory fees to complete the relevant forms, preparing supporting calculations and handling associated interactions with global, fed and state taxing authorities. This assumes that the wind-down period does not straddle two tax years, which wo

  60. Slide 60: Annex – Counterparty Dispute

    Annex 4 – Counterparty Dispute

  61. Slide 61: Counterparty Update August 14, 2022

    Counterparty Update August 14, 2022 Highly Confidential Cleansing Material Subject to FRE 408 & State Law Equivalents Preliminary and Subject to Material Change endo.com

  62. Slide 62: Disclaimer

    Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you have executed with the Company. All communications or

  63. Slide 63: Overview of Termination Notice

    Overview â–º On August 12, without warning, Endo received a Termination Notice (Notice) from a contract counterparty (Counterparty) alleging incurable, material breaches by Endo of the parties’ agreement (Agreement). â–º The Agreement provides for termination upon a material breach following a cure

  64. Slide 64: Potential Economic Impact

    Potential Economic Impact â–º The products subject to the Agreement are forecast to generate gross profit of approximately: – $1M in 2022 – $20M in 2023 – $40M in 2024 – $55M in 2025 – $50M in 2026 â–º The Company has already paid the Counterparty approximately $40M in upfront and milestone payments

  65. Slide 65: Annex – Q2 2022 Flash Results

    Annex 5 – Q2 2022 Flash Results

  66. Slide 66: Preliminary 2Q22A and FY22E Financial Results

    Preliminary 2Q22A and FY22E Financial Results (DRAFT) July 31, 2022 Confidential Subject to Confidentiality Agreement Cleansing Material Subject to FRE 408 & State Law Equivalents Preliminary and Subject to Material Change endo.com

  67. Slide 67: Disclaimer

    Disclaimer This document has been prepared by Endo International plc (“Endo” or the “Company”) and its advisors from information provided by Company management and other sources, and is subject in all respects to the confidentiality agreement you have executed with the Company. All communications or

  68. Slide 68: 2Q22A and FY22E Pre-tax unlevered FCF favorable to May LTP

    2Q22A and FY22E Pre-tax unlevered FCF are favorable to the MayLTP Preliminary Subject 2Q22 FY2022 to Material Change $ million MayLTP JulLBE Δ MayLTP JulLBE Δ Branded $ 209 $ 219 $ 10 $ 903 $ 908 $ 5 Sterile Injectable 114 123 9 581 580 (1) Generics 180 203 23 665 700 34 International 20 24 3 81 8

  69. Slide 69: 2Q22A ending cash favorable to May LTP

    2Q22A ending cash is favorable to the MayLTP Preliminary Subject 2Q22 to Material Change $ million MayLTP JulLBE Δ Pre-tax uFCF $ 117 $ 157 $ 40 (-) Cash Taxes (3) (4) (1) (-) TLC Escrow—(85) (85) (-) Litigation/Advisors (202) (129) 74 SQ uFCF $ (88) $ (61) $ 27 (-) Interest/fin pmts (194) (156) 39

  70. Slide 70: Annex – Approved Budget

    Annex 6 – Approved Budget

  71. Slide 71: Project Zed Approved Budget Weekly Cash Flow

    Project Zed Approved Budget 1 Weekly Cash Flow – Debtor Monthly View (USD in $ millions, unless otherwise indicated) Debtor 13 8/15 - 8/31 Month Aug-22 Sep-22 Oct-22 Nov-22 Dec-22 Jan-23 Feb-23 Mar-23 Apr-23 May-23 Jun-23 Jul-23 Total Operating Receipts Product Sales Receipts $54 $368 $260 $201 $247

  72. Slide 72: Project Zed Approved Budget 13-Week Cash Flow

    Project Zed Approved Budget 13-Week Cash Flow – Debtor Entities (USD in $000s, unless otherwise indicated) Targeted Ch. 11 Filing Week Debtor Fcst Fcst Fcst Fcst Fcst Fcst Fcst Fcst Fcst Fcst Fcst Fcst Fcst 13 Forecast Week No. Week 1 Week 2 Week 3 Week 4 Week 5 Week 6 Week 7 Week 8 Week 9 Week 10 W

Endo International — Investor Presentation (August 2022) on 6ix